Source link : https://newshealth.biz/health-news/jak1-inhibitor-zemprocitinib-hits-targets-in-refractory-ra/
Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds. Medscape Medical News Source link : https://www.medscape.com/viewarticle/selective-jak1-inhibitor-zemprocitinib-hits-efficacy-targets-2026a1000iy3?src=rss Author : Publish date : 2026-06-06 15:05:00 Copyright for syndicated content belongs to the linked Source.
The post JAK1 Inhibitor Zemprocitinib Hits Targets in Refractory RA first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-06 15:05:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8